Hybrid CAR and Hybrid TCR cells to treat infectious diseases Ghent University
The present invention relates to the field of controlling infections where pathogens can be targeted at the host cell-associated and cell-free stages of their life cycles with edited T Cell Receptor (TCR) or Chimeric Antigen Receptor (CAR) cells which further secrete pathogen- specific antibodies. An example of such pathogen is human immunodeficiency virus (HIV). Indeed, the present invention discloses that CAR cells producing broadly neutralizing anti-HIV antibodies are capable to both destroy HIV-infected cells and non-cell associated HIV particles that become released from HIV-infected ...